CL2023002201A1 - Forma cristalina de un derivado de piperazinil-tiazol - Google Patents
Forma cristalina de un derivado de piperazinil-tiazolInfo
- Publication number
- CL2023002201A1 CL2023002201A1 CL2023002201A CL2023002201A CL2023002201A1 CL 2023002201 A1 CL2023002201 A1 CL 2023002201A1 CL 2023002201 A CL2023002201 A CL 2023002201A CL 2023002201 A CL2023002201 A CL 2023002201A CL 2023002201 A1 CL2023002201 A1 CL 2023002201A1
- Authority
- CL
- Chile
- Prior art keywords
- crystalline form
- piperazinyl
- thiazole derivative
- trifluoromethyl
- pharmaceutical compositions
- Prior art date
Links
- WQFWIVTXNKRNJZ-UHFFFAOYSA-N 2-piperazin-1-yl-1,3-thiazole Chemical class C1CNCCN1C1=NC=CS1 WQFWIVTXNKRNJZ-UHFFFAOYSA-N 0.000 title 1
- 108010061300 CXCR3 Receptors Proteins 0.000 abstract 2
- 102000011963 CXCR3 Receptors Human genes 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a una forma cristalina de 1-(R)-2-(2-Hidroxi-etil)-4-2-trifluorometil-4-(2-trifluorometil-pirimidin-5-il)-tiazol-5-il -piperazin-1-il -2-(3-metil-1,2,4 triazol-1-il)-etanona, procesos para la preparación de esta, composiciones farmacéuticas que comprenden esta forma cristalina, composiciones farmacéuticas preparadas a partir de estas formas cristalinas y su uso como moduladores de receptor de CXCR3 en el tratamiento de diversas enfermedades y trastornos con relación al receptor de CXCR3 y sus ligandos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2021051983 | 2021-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023002201A1 true CL2023002201A1 (es) | 2024-02-16 |
Family
ID=80222235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023002201A CL2023002201A1 (es) | 2021-01-28 | 2023-07-26 | Forma cristalina de un derivado de piperazinil-tiazol |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240092772A1 (es) |
| EP (1) | EP4284508A1 (es) |
| JP (1) | JP2024504785A (es) |
| KR (1) | KR20230137401A (es) |
| CN (1) | CN117015541A (es) |
| AU (1) | AU2022215025A1 (es) |
| CA (1) | CA3205745A1 (es) |
| CL (1) | CL2023002201A1 (es) |
| IL (1) | IL304683A (es) |
| MX (1) | MX2023008659A (es) |
| TW (1) | TW202246258A (es) |
| WO (1) | WO2022162017A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024052445A1 (en) | 2022-09-09 | 2024-03-14 | Idorsia Pharmaceuticals Ltd | Pharmaceutical combination comprising an anti-cd3 antibody and a cxcr3 antagonist |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3245203T1 (sl) | 2015-01-15 | 2019-03-29 | Idorsia Pharmaceuticals Ltd | Derivati hiroksialkil-piperazina kot modulatorji receptorja CXCR3 |
-
2022
- 2022-01-26 MX MX2023008659A patent/MX2023008659A/es unknown
- 2022-01-26 KR KR1020237029052A patent/KR20230137401A/ko unknown
- 2022-01-26 AU AU2022215025A patent/AU2022215025A1/en active Pending
- 2022-01-26 JP JP2023545827A patent/JP2024504785A/ja active Pending
- 2022-01-26 WO PCT/EP2022/051786 patent/WO2022162017A1/en active Application Filing
- 2022-01-26 EP EP22702924.6A patent/EP4284508A1/en active Pending
- 2022-01-26 CA CA3205745A patent/CA3205745A1/en active Pending
- 2022-01-26 US US18/263,318 patent/US20240092772A1/en active Pending
- 2022-01-26 CN CN202280011642.4A patent/CN117015541A/zh active Pending
- 2022-01-27 TW TW111103606A patent/TW202246258A/zh unknown
-
2023
- 2023-07-24 IL IL304683A patent/IL304683A/en unknown
- 2023-07-26 CL CL2023002201A patent/CL2023002201A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL304683A (en) | 2023-09-01 |
| TW202246258A (zh) | 2022-12-01 |
| JP2024504785A (ja) | 2024-02-01 |
| AU2022215025A1 (en) | 2023-09-14 |
| KR20230137401A (ko) | 2023-10-04 |
| WO2022162017A1 (en) | 2022-08-04 |
| MX2023008659A (es) | 2023-08-01 |
| EP4284508A1 (en) | 2023-12-06 |
| CA3205745A1 (en) | 2022-08-04 |
| CN117015541A (zh) | 2023-11-07 |
| US20240092772A1 (en) | 2024-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122575T1 (el) | Φαρμακοτεχνικες μορφες διστρωματικου δισκιου | |
| CO2019012359A2 (es) | Oxadiazoles fungicidas | |
| UY38449A (es) | Fungicidas de tolilo sustituido | |
| CO2017004471A2 (es) | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos | |
| CR20170478A (es) | Compuestos novedosos | |
| CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
| CL2020001762A1 (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464) | |
| HN2011001593A (es) | Piridiloxi-indoles del vegf-r2 y uso de los mismos para el tratmiento de enfermedades | |
| UY36713A (es) | Triazoles para el tratamiento de enfermedades desmielinizantes | |
| UY38806A (es) | Compuestos inhibidores tricíclicos de kars dependientes de akr1c3, composiciones y sus usos | |
| CL2021003247A1 (es) | Inhibidores de vía integrada para respuesta al estrés. | |
| CO6630139A2 (es) | Aptámeros par b-bgf y su uso en el tratamiento de enfermedades y transtornos mediados por b-ngf | |
| CL2008002131A1 (es) | Compuestos heterociclos de amidas derivados de pirimidinas sustituidas por heterociclos y heterobiciclicos, inhibidores de la proteincinasa; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades proliferativas, neurologicas o neurodegenerativas, cardiovasculares, virosica o fungicas. | |
| CL2020001090A1 (es) | Compuesto de pirimidina como inhibidor de las janocinasas. | |
| CL2023002201A1 (es) | Forma cristalina de un derivado de piperazinil-tiazol | |
| ECSP22018571A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| UY35293A (es) | Isotiazoles sustituidos con amino | |
| CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| CL2021003455A1 (es) | Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida | |
| UY38841A (es) | Composiciones para controlar parásitos | |
| CL2023003518A1 (es) | Nuevas sales y formas cristalinas de sales de n,n-dimetiltriptamina | |
| CL2021000538A1 (es) | Pirazoles fungicidas sustituidos con nitroanilino | |
| HN2006007774A (es) | Imidazoles sustituidos con heterociclilamida | |
| DOP2006000024A (es) | Tiazolidinonas, su preparación y su uso como medicamento |